Published in Cancer Res on June 15, 2005
DNA repair dysregulation from cancer driver to therapeutic target. Nat Rev Cancer (2012) 2.70
Imaging primary lung cancers in mice to study radiation biology. Int J Radiat Oncol Biol Phys (2010) 1.48
Modulating the tumor microenvironment to increase radiation responsiveness. Cancer Biol Ther (2009) 1.18
Lithium-mediated protection of hippocampal cells involves enhancement of DNA-PK-dependent repair in mice. J Clin Invest (2009) 1.13
Role of DNA-dependent protein kinase catalytic subunit in cancer development and treatment. Transl Cancer Res (2012) 1.08
Preclinical pharmacokinetics and metabolism of a novel prototype DNA-PK inhibitor NU7026. Br J Cancer (2005) 1.07
Inhibition of DNA double-strand break repair by the dual PI3K/mTOR inhibitor NVP-BEZ235 as a strategy for radiosensitization of glioblastoma. Clin Cancer Res (2013) 1.07
Small Molecules, Inhibitors of DNA-PK, Targeting DNA Repair, and Beyond. Front Pharmacol (2013) 1.05
New tricks for old drugs: the anticarcinogenic potential of DNA repair inhibitors. J Mol Histol (2006) 1.02
Impact of stromal sensitivity on radiation response of tumors implanted in SCID hosts revisited. Cancer Res (2010) 1.01
Targeting abnormal DNA double strand break repair in cancer. Cell Mol Life Sci (2010) 1.01
Development of a resistance-like phenotype to sorafenib by human hepatocellular carcinoma cells is reversible and can be delayed by metronomic UFT chemotherapy. Neoplasia (2010) 0.99
Serine/threonine protein phosphatase 6 modulates the radiation sensitivity of glioblastoma. Cell Death Dis (2011) 0.98
Indolyl-quinuclidinols inhibit ENOX activity and endothelial cell morphogenesis while enhancing radiation-mediated control of tumor vasculature. FASEB J (2009) 0.94
DNA protein kinase-dependent G2 checkpoint revealed following knockdown of ataxia-telangiectasia mutated in human mammary epithelial cells. Cancer Res (2008) 0.93
Inhibiting the DNA damage response as a therapeutic manoeuvre in cancer. Br J Pharmacol (2013) 0.93
PP6 regulatory subunit R1 is bidentate anchor for targeting protein phosphatase-6 to DNA-dependent protein kinase. J Biol Chem (2012) 0.91
Irinotecan and DNA-PKcs inhibitors synergize in killing of colon cancer cells. Invest New Drugs (2011) 0.91
Influence of bone marrow-derived hematopoietic cells on the tumor response to radiotherapy: experimental models and clinical perspectives. Cell Cycle (2009) 0.90
DNA Damage Signalling and Repair Inhibitors: The Long-Sought-After Achilles' Heel of Cancer. Biomolecules (2015) 0.88
Preclinical study of the DNA repair inhibitor Dbait in combination with chemotherapy in colorectal cancer. J Gastroenterol (2011) 0.87
Molecular targets for tumor radiosensitization. Chem Rev (2009) 0.86
The effect of DNA-dependent protein kinase on adeno-associated virus replication. PLoS One (2010) 0.86
A preclinical study combining the DNA repair inhibitor Dbait with radiotherapy for the treatment of melanoma. Neoplasia (2014) 0.85
NSCLC cells demonstrate differential mode of cell death in response to the combined treatment of radiation and a DNA-PKcs inhibitor. Oncotarget (2015) 0.85
Effects of the novel DNA dependent protein kinase inhibitor, IC486241, on the DNA damage response to doxorubicin and cisplatin in breast cancer cells. Invest New Drugs (2011) 0.85
FBXW7 Facilitates Nonhomologous End-Joining via K63-Linked Polyubiquitylation of XRCC4. Mol Cell (2016) 0.82
Oncolytic virus-mediated tumor radiosensitization in mice through DNA-PKcs-specific shRNA. Transl Cancer Res (2012) 0.81
Inhibiting vasculogenesis after radiation: a new paradigm to improve local control by radiotherapy. Semin Radiat Oncol (2013) 0.81
Zerumbone increases oxidative stress in a thiol-dependent ROS-independent manner to increase DNA damage and sensitize colorectal cancer cells to radiation. Cancer Med (2014) 0.80
Radiosensitization and growth inhibition of cancer cells mediated by an scFv antibody gene against DNA-PKcs in vitro and in vivo. Radiat Oncol (2010) 0.80
Preventing Damage Limitation: Targeting DNA-PKcs and DNA Double-Strand Break Repair Pathways for Ovarian Cancer Therapy. Front Oncol (2015) 0.78
Genotypic characteristics of resistant tumors to pre-operative ionizing radiation in rectal cancer. World J Gastrointest Oncol (2014) 0.77
Determinates of tumor response to radiation: tumor cells, tumor stroma and permanent local control. Radiother Oncol (2014) 0.77
Optical Imaging of Tumor Response to Hyperbaric Oxygen Treatment and Irradiation in an Orthotopic Mouse Model of Head and Neck Squamous Cell Carcinoma. Mol Imaging Biol (2015) 0.76
Strategies for targeting the DNA damage response for cancer therapeutics. Chin J Cancer (2012) 0.76
Experimental infection of North American birds with the New York 1999 strain of West Nile virus. Emerg Infect Dis (2003) 7.96
CAL-101, a p110delta selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability. Blood (2010) 4.69
Hyperactivation of phosphatidylinositol-3 kinase promotes escape from hormone dependence in estrogen receptor-positive human breast cancer. J Clin Invest (2010) 3.53
Genome-wide association study identifies susceptibility loci for polycystic ovary syndrome on chromosome 2p16.3, 2p21 and 9q33.3. Nat Genet (2010) 3.02
Inhibition of poly(ADP-ribose) polymerase enhances cell death and improves tumor growth delay in irradiated lung cancer models. Clin Cancer Res (2007) 2.52
Inhibition of mammalian target of rapamycin or apoptotic pathway induces autophagy and radiosensitizes PTEN null prostate cancer cells. Cancer Res (2006) 2.21
Insights into ALK-driven cancers revealed through development of novel ALK tyrosine kinase inhibitors. Cancer Res (2011) 2.06
Genome-wide association study identifies eight new risk loci for polycystic ovary syndrome. Nat Genet (2012) 2.02
SU11248 maintenance therapy prevents tumor regrowth after fractionated irradiation of murine tumor models. Cancer Res (2003) 2.00
The receptor tyrosine kinase inhibitor SU11248 impedes endothelial cell migration, tubule formation, and blood vessel formation in vivo, but has little effect on existing tumor vessels. Angiogenesis (2004) 1.87
Targeting nonclassical oncogenes for therapy in T-ALL. Cancer Cell (2012) 1.86
Avian hosts for West Nile virus in St. Tammany Parish, Louisiana, 2002. Am J Trop Med Hyg (2005) 1.80
Cytosolic phospholipase A2 and lysophospholipids in tumor angiogenesis. J Natl Cancer Inst (2010) 1.78
Proper inference from Simon's two-stage designs. Stat Med (2008) 1.75
West Nile virus antibodies in Colombian horses. Emerg Infect Dis (2005) 1.65
Inhibition of alpha(v)beta3 integrin survival signaling enhances antiangiogenic and antitumor effects of radiotherapy. Clin Cancer Res (2005) 1.64
Effects of intercellular adhesion molecule 1 (ICAM-1) null mutation on radiation-induced pulmonary fibrosis and respiratory insufficiency in mice. J Natl Cancer Inst (2002) 1.63
Histone deacetylase (HDAC) inhibitor LBH589 increases duration of gamma-H2AX foci and confines HDAC4 to the cytoplasm in irradiated non-small cell lung cancer. Cancer Res (2006) 1.58
Autophagy for cancer therapy through inhibition of pro-apoptotic proteins and mammalian target of rapamycin signaling. J Biol Chem (2006) 1.55
DNA-Mutation Inventory to Refine and Enhance Cancer Treatment (DIRECT): a catalog of clinically relevant cancer mutations to enable genome-directed anticancer therapy. Clin Cancer Res (2013) 1.54
The clinical impact of the radiology report in wheezing and nonwheezing febrile children: a survey of clinicians. Pediatr Radiol (2009) 1.54
Enhanced radiation damage of tumor vasculature by mTOR inhibitors. Oncogene (2005) 1.54
Increased expression of nuclear factor E2 p45-related factor 2 (NRF2) in head and neck squamous cell carcinomas. Head Neck (2006) 1.52
Interactive competition between homologous recombination and non-homologous end joining. Mol Cancer Res (2003) 1.49
SLC1A5 mediates glutamine transport required for lung cancer cell growth and survival. Clin Cancer Res (2012) 1.46
Lithium treatment prevents neurocognitive deficit resulting from cranial irradiation. Cancer Res (2006) 1.45
XIAP and survivin as therapeutic targets for radiation sensitization in preclinical models of lung cancer. Oncogene (2004) 1.44
Incidence and outcome of chronic graft-versus-host disease using National Institutes of Health consensus criteria. Biol Blood Marrow Transplant (2007) 1.44
Pharmacologic enhancement of rat skin flap survival with topical oleic acid. Plast Reconstr Surg (2004) 1.40
Predictive and pharmacodynamic biomarker studies in tumor and skin tissue samples of patients with recurrent or metastatic squamous cell carcinoma of the head and neck treated with erlotinib. J Clin Oncol (2007) 1.40
Checkpoint kinase 2-mediated phosphorylation of BRCA1 regulates the fidelity of nonhomologous end-joining. Cancer Res (2006) 1.38
Molecular imaging of vascular endothelial growth factor receptor 2 expression using targeted contrast-enhanced high-frequency ultrasonography. J Ultrasound Med (2007) 1.38
Survivin as a therapeutic target for radiation sensitization in lung cancer. Cancer Res (2004) 1.33
Integrin alpha v beta 3 antagonist Cilengitide enhances efficacy of radiotherapy in endothelial cell and non-small-cell lung cancer models. Int J Radiat Oncol Biol Phys (2006) 1.30
A study on adaptive IMRT treatment planning using kV cone-beam CT. Radiother Oncol (2007) 1.30
Avian mortality surveillance for West Nile virus in Colorado. Am J Trop Med Hyg (2007) 1.26
Validation of the essential ClpP protease in Mycobacterium tuberculosis as a novel drug target. J Bacteriol (2011) 1.25
VeriStrat classifier for survival and time to progression in non-small cell lung cancer (NSCLC) patients treated with erlotinib and bevacizumab. Lung Cancer (2009) 1.24
Noninvasive assessment of cancer response to therapy. Nat Med (2008) 1.23
Relationship between retention of a vascular endothelial growth factor receptor 2 (VEGFR2)-targeted ultrasonographic contrast agent and the level of VEGFR2 expression in an in vivo breast cancer model. J Ultrasound Med (2008) 1.22
Akt is a major angiogenic mediator downstream of the Ang1/Tie2 signaling pathway. Exp Cell Res (2004) 1.22
GSK-3β: A Bifunctional Role in Cell Death Pathways. Int J Cell Biol (2012) 1.21
Impact of inhomogeneity corrections on dose coverage in the treatment of lung cancer using stereotactic body radiation therapy. Med Phys (2007) 1.20
Phosphatidylinositol 3-kinase/Akt signaling in the response of vascular endothelium to ionizing radiation. Cancer Res (2002) 1.20
Targeted nanoparticles that deliver a sustained, specific release of Paclitaxel to irradiated tumors. Cancer Res (2010) 1.17
Prospective feasibility trial of radiotherapy target definition for head and neck cancer using 3-dimensional PET and CT imaging. J Nucl Med (2004) 1.17
Nuclear survivin predicts recurrence and poor survival in patients with resected nonsmall cell lung carcinoma. Cancer (2005) 1.16
Integrin-mediated targeting of drug delivery to irradiated tumor blood vessels. Cancer Cell (2003) 1.14
Lithium-mediated protection of hippocampal cells involves enhancement of DNA-PK-dependent repair in mice. J Clin Invest (2009) 1.13
The kinase activity of DNA-PK is required to protect mammalian telomeres. DNA Repair (Amst) (2004) 1.11
SU11248 (sunitinib) sensitizes pancreatic cancer to the cytotoxic effects of ionizing radiation. Int J Radiat Oncol Biol Phys (2008) 1.11
Classification by mass spectrometry can accurately and reliably predict outcome in patients with non-small cell lung cancer treated with erlotinib-containing regimen. J Thorac Oncol (2009) 1.10
West Nile virus infection in free-ranging squirrels in Illinois. J Vet Diagn Invest (2004) 1.09
Inhibition of glycogen synthase kinase 3 beta attenuates neurocognitive dysfunction resulting from cranial irradiation. Cancer Res (2008) 1.09
Phantom validation of coregistration of PET and CT for image-guided radiotherapy. Med Phys (2004) 1.07
HOXA11 is critical for development and maintenance of uterosacral ligaments and deficient in pelvic prolapse. J Clin Invest (2008) 1.07
Anxiolytic- and antidepressant-like profiles of the galanin-3 receptor (Gal3) antagonists SNAP 37889 and SNAP 398299. Proc Natl Acad Sci U S A (2005) 1.06
A new class of molecular targeted radioprotectors: GSK-3beta inhibitors. Int J Radiat Oncol Biol Phys (2010) 1.05
Measuring tumor perfusion in control and treated murine tumors: correlation of microbubble contrast-enhanced sonography to dynamic contrast-enhanced magnetic resonance imaging and fluorodeoxyglucose positron emission tomography. J Ultrasound Med (2007) 1.05
Estimating the economic burden of food-induced allergic reactions and anaphylaxis in the United States. J Allergy Clin Immunol (2011) 1.05
Characterizing tumor response to chemotherapy at various length scales using temporal diffusion spectroscopy. PLoS One (2012) 1.05
In regard to Shah. Int J Radiat Oncol Biol Phys (2013) 1.05
Proteolytic surface functionalization enhances in vitro magnetic nanoparticle mobility through extracellular matrix. Nano Lett (2006) 1.04
Radiosensitization of lung cancer by nutlin, an inhibitor of murine double minute 2. Mol Cancer Ther (2006) 1.04
Characterization of superparamagnetic nanoparticle interactions with extracellular matrix in an in vitro system. Ann Biomed Eng (2006) 1.04
Shared gene expression profiles in individuals with autoimmune disease and unaffected first-degree relatives of individuals with autoimmune disease. Hum Mol Genet (2005) 1.04
Smoking-related genomic signatures in non-small cell lung cancer. Am J Respir Crit Care Med (2008) 1.03
Protein kinase B/Akt-dependent phosphorylation of glycogen synthase kinase-3beta in irradiated vascular endothelium. Cancer Res (2006) 1.02
DNA-dependent protein kinase inhibitors as drug candidates for the treatment of cancer. Mol Cancer Ther (2003) 1.01
Fruit and vegetable intakes are associated with lower risk of colorectal adenomas. J Nutr (2008) 1.01
Vascular endothelial growth factor tyrosine kinase inhibitor AZD2171 and fractionated radiotherapy in mouse models of lung cancer. Cancer Res (2006) 1.00
Molecular strategies targeting the host component of cancer to enhance tumor response to radiation therapy. Int J Radiat Oncol Biol Phys (2006) 1.00
Tumor-targeted delivery of liposome-encapsulated doxorubicin by use of a peptide that selectively binds to irradiated tumors. J Control Release (2010) 0.99
Analysis of clinical characteristics in large-scale Chinese women with polycystic ovary syndrome. Neuro Endocrinol Lett (2007) 0.99
Clinicopathologic predictors of sentinel lymph node metastasis in thin melanoma. J Clin Oncol (2013) 0.98
Effects of isoform-selective phosphatidylinositol 3-kinase inhibitors on osteoclasts: actions on cytoskeletal organization, survival, and resorption. J Biol Chem (2013) 0.96
Correlation between estimates of tumor perfusion from microbubble contrast-enhanced sonography and dynamic contrast-enhanced magnetic resonance imaging. J Ultrasound Med (2006) 0.96
Radiation-guided drug delivery to mouse models of lung cancer. Clin Cancer Res (2010) 0.95
Sonographic depiction of microvessel perfusion: principles and potential. J Ultrasound Med (2004) 0.95
Interactions of the p53 protein family in cellular stress response in gastrointestinal tumors. Mol Cancer Ther (2010) 0.94
Passive West Nile virus antibody transfer from maternal Eastern screech-owls (Megascops asio) to progeny. Avian Dis (2006) 0.94
Radiation induces an antitumour immune response to mouse melanoma. Int J Radiat Biol (2009) 0.92
Correlation of quantified contrast-enhanced sonography with in vivo tumor response. J Ultrasound Med (2010) 0.92
AT-101, a pan-Bcl-2 inhibitor, leads to radiosensitization of non-small cell lung cancer. J Thorac Oncol (2010) 0.91
Cytoplasmic clusterin expression is associated with longer survival in patients with resected non small cell lung cancer. Cancer Epidemiol Biomarkers Prev (2007) 0.91